Phase I and pharmacokinetic study of irinotecan administered as a low- dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1897-1905

  Herben, Virginie M M ^a   Schellens, Jan H M ^a   Swart, Martha ^a   Gruia, Gabriela ^a   Vernillet, Laurent ^a   Beijnen, Jos H ^a   Ten Bokkel Huinink, Wim W ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CIPROFLOXACIN; IRINOTECAN; LOPERAMIDE; OCTREOTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0032998172     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1897     Document Type: Article

References (29)

1. O'Reilly S, Rowinsky EK: The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol 24:47-70, 1996
2. Masuda N, Kudoh S, Fukuoka M: Irinotecan (CPT-11): Pharmacology and clinical applications. Crit Rev Oncol Hematol 24:3-26, 1996
3. Hsiang Y-H, Liu LF, Wall ME, et al: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49:4385-4389, 1989
4. Burris HA III, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 84:1816-1820, 1992
5. Supko JG, Plowman J, Dyker DJ, et al: Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33:432, 1992 (abstr)
6. Houghton PJ, Cheshire PJ, Hallman JD II, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
7. Furuta T, Yokokura T: Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Jpn J Cancer Chemother 17:121-130, 1990
8. Bissery MC, Vrignaud P, Lavelle F, et al: Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7:437-460, 1996
9. Shimada Y, Yashino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer: CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909-913, 1993
10. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
11. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 15:2910-2919, 1997
12. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
13. Hochster H, Liebes L, Sorich J, et al: Effect of prolonged topotecan infusion on topoisomerase I levels: A phase I and pharmacodynamic study. Clin Cancer Res 3:1245-1252, 1997
14. World Health Organization: Handbook for Reporting Results of Cancer Treatment (WHO publication no. 48). Geneva, Switzerland, World Health Organization, 1979
15. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, National Cancer Institute, 1998
16. Herben VMM, Mazee D, Van Gortel-Van Zomeren DM, et al: Sensitive determination of the carboxylate and lactone forms of the novel antitumor drug irinotecan and its active metabolite in plasma by HPLC. J Liquid Chromatography Related Technol 21:1541-1558, 1998
17. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
18. Cunningham D, Van Cutsem E, Ten Bokkel Huinink W, et al: Open-label multicentre phase II study to confirm efficacy and safety of irinotecan-HC1 (CPT-11) in metastatic 5-FU resistant colorectal cancer. Br J Cancer 74:18, 1996 (abstr)
19. Gupta E, Mick R, Ramirez J, et al: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510, 1997
20. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995
21. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695, 1996
22. Tanizawa A, Fujimori A, Fujimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994
23. Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1721, 1990
24. Kaneda N, Yokokura T: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990
25. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
26. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of non-small cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
27. Rivory LP, Bowles MR, Robert J, et al: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111, 1996
28. Gerrits CJH, Schellens JHM, Burris H, et al: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69-75, 1999
29. Abigerges D, Chabot GG, Armand J-P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995